Can immunotherapy by gene transfer tip the balance against colorectal cancer?

S. M. Todryk, H. Chong, R. G. Vile, H. Pandha, N. R. Lemoine

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a 'cancer vaccine', or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.

Original languageEnglish (US)
Pages (from-to)445-449
Number of pages5
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Can immunotherapy by gene transfer tip the balance against colorectal cancer?'. Together they form a unique fingerprint.

Cite this